Elucidating the role of STAT3 and VEGFA in Breast Cancer and Diabetes Mellitus Type 2 patients

Abstract

Breast Cancer and Diabetes Mellitus type 2 are complex and leading diseases worldwide resulting in huge morbities. These are characterized with some common risk factors including oxidative stress, sedentary lifestyle, obesity, family history, poor diet, hyperlipidemia, hyperglycemia, hyperinsulinemia, stress, elevated blood pressure, smoking, and high cholesterol. Also, these diseases share complicated pathophysiology, and various etiologies. There are certain genetic factors influencing the severity of the diseases. There are many people who suffer from both diseases because of the uncontrolled and unpredictable signaling process. The identification of crucial biomarkers is inevitable for designing of drug that can be targeted to the desired area lessening the pathogenesis. The present medications available are either solely for the Diabetes or Breast cancer because the etiology or mode of other disease development is still not well studied. The present study aims to find more effective biomarker to be targeted by drugs that can lessen the severity of disease by lowering the expression of these biomarkers. Two genes namely STAT3 and VEGFA were selected from JAK/STAT signaling pathway that had roles in carcinogenesis, high blood pressure induction, hyperinsulinemia, and hyperglycemia. The blood of patients was obtained to get RNA extracted by Trizol method which was later quantified to check the purity of RNA. cDNA was then synthesized. RT PCR of STAT3 and VEGFA showed higher expression of these genes in disease individuals as compared to healthy ones. The higher expression of STAT3 causes the high expression of VEGFA as well. The statistical analysis of RT-PCR results proved these genes to be possible effective biomarkers for Breast cancer and Diabetes Mellitus Type 2 patients